Evidence map›Paper›PMID 37041020›Full record

ArticleBMJ open gastroenterology2023

Quality of life measures in dysplastic Barrett's oesophagus are comparable to patients with non-dysplastic Barrett's oesophagus and do not improve after endoscopic therapy.

Elizabeth Ratcliffe, James Britton, Calvin Heal, Richard Keld, Mark Murgatroyd, Robert Willert, John McLaughlin, Shaheen Hamdy, Yeng Ang

Open access · goldAbstract read
In one paragraph

Article in BMJ open gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Elizabeth RatcliffeGastroenterology Department, Wrightington, Wigan and Leigh NHS Foundation Trust, Wigan, UK elizabeth.ratcliffe@wwl.nhs.uk.ORCID 0000-0001-6521-2133
James BrittonDepartment of Gastroenterology, Northern Care Alliance NHS Foundation Trust, Salford, Manchester, UK.
Calvin HealSchool of Health Sciences, Division of Population Health, Health Services Research & Primary Care, The University of Manchester, Manchester, UK.
Richard KeldGastroenterology Department, Wrightington, Wigan and Leigh NHS Foundation Trust, Wigan, UK.
Mark MurgatroydGastroenterology Department, Bolton NHS Foundation Trust, Bolton, UK.
Robert WillertGastroenterology Department, Manchester University NHS Foundation Trust, Manchester, UK.
John McLaughlinDivision of Diabetes, Endocrinology and Gastroenterology, Faculty of Medical and Human Sciences, The University of Manchester, Manchester, UK.ORCID 0000-0001-6158-5135
Shaheen HamdyDivision of Diabetes, Endocrinology and Gastroenterology, Faculty of Medical and Human Sciences, The University of Manchester, Manchester, UK.ORCID 0000-0001-9640-7427
Yeng AngDivision of Diabetes, Endocrinology and Gastroenterology, Faculty of Medical and Human Sciences, The University of Manchester, Manchester, UK.
University of Manchester · GBWrightington, Wigan and Leigh NHS Foundation Trust · GBBolton NHS Foundation Trust · GBManchester Academic Health Science Centre · GBManchester University NHS Foundation Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveBarrett's oesophagus (BO) is a precursor lesion, via dysplastic phases, to oesophageal adenocarcinoma. Although overall risk from BO is low, it has been shown to adversely affect health-related quality of life (HRQOL). The aim was to compare dysplastic BO patients' HRQOL pre-endoscopic therapy (pre-ET) and post-ET. The pre-ET BO group was also compared with other cohorts: non-dysplastic BO (NDBO), those with colonic polyps, gastro-oesophageal reflux disease (GORD) and healthy volunteers.

designParticipants in the pre-ET cohort were recruited prior to their endotherapy and HRQOL questionnaires provided pre-ET and post-ET. Wilcoxon rank test was used to compare the pre-ET and post-ET findings. The Pre-ET group was compared to the other cohorts' HRQOL results using multiple linear regression analysis.

resultsPre-ET group of 69 participants returned the questionnaires prior to and 42 post-ET. Both the pre-ET and post-ET group showed similar levels of cancer worry, despite the treatment. No statistical significance was found for symptoms scores, anxiety and depression or general health measures with the Short Form-36 (SF-36) Score. Education for the BO patients was overall lacking with many of the pre-ET group still reporting unanswered questions about their disease.The Pre-ET group was compared with NDBO group (N=379), GORD (N=132), colonic polyp patients (N=152) and healthy volunteers (N=48). Cancer worry was similar between the NDBO group and the Pre-ET group, despite their lower risk of progression. GORD patients had worse symptom scores from a reflux and heartburn perspective. Only the healthy group has significantly better scores in the SF-36 and improved hospital anxiety and depression scores.

conclusionThese findings suggest that there is a need to improve HRQOL for patients with BO. This should include improved education and devising-specific patient-reported outcome measures for BO to capture relevant areas of HRQOL in future studies.

Indexed as

AdenocarcinomaBarrett EsophagusEsophageal NeoplasmsGastroesophageal RefluxEndoscopyHumansQuality of LifeBARRETT'S METAPLASIABARRETT'S OESOPHAGUSDYSPLASIAENDOSCOPYQUALITY OF LIFE

Identifiers

PMID37041020
PMCPMC10105999
OpenAlexW4364378434

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.